ReNeuron Group has announced its progress with the ongoing Phase 1/2 clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). Positive efficacy has been seen and sustained in the first patient cohort in the Phase 2 part of the study.
The company’s RP clinical programme is aided by an Orphan Drug Designation in both Europe and the US, as well as Fast Track designation from the FDA.
Olav Hellebø, ReNeuron’s CEO, said: “We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing Phase 1/2 study with our hRPC cell therapy candidate for retinitis pigmentosa. We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month.”